Welcome to our dedicated page for Si-Bone news (Ticker: SIBN), a resource for investors and traders seeking the latest updates and insights on Si-Bone stock.
SI-BONE, Inc. (NASDAQ: SIBN) is a medical device company focused on minimally invasive surgical technologies for sacropelvic disorders, including sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, spinopelvic and sacropelvic fixation, and pelvic trauma. This news page aggregates company press releases and market updates related to SIBN stock and SI-BONE’s sacropelvic platform.
Investors following SI-BONE news can expect regular updates on quarterly and annual financial results, preliminary revenue announcements, and changes to financial guidance. Recent communications have highlighted double-digit worldwide and U.S. revenue growth, gross margin performance, adjusted EBITDA trends, and cash and cash equivalents. The company also reports operational metrics such as the number of active U.S. physicians using its technologies and revenue per sales territory.
Beyond earnings, SI-BONE’s news flow includes information on reimbursement developments, such as New Technology Add-on Payments and other payment designations for procedures involving products like iFuse TORQ TNT and iFuse Bedrock Granite. The company also issues 8-K-linked press releases covering leadership and board changes, including retirements, consulting agreements, and commercial leadership transitions.
Another recurring theme in SI-BONE news is participation in healthcare and medtech investor conferences hosted by firms such as Piper Sandler, Morgan Stanley, Canaccord Genuity, Truist Securities, and Goldman Sachs. These events often feature fireside chats or presentations where management discusses sacropelvic technologies, clinical evidence, and financial performance, with webcasts made available through the investors section of SI-BONE’s website.
For anyone tracking SIBN, this page offers a centralized view of SI-BONE’s earnings releases, preliminary updates, conference appearances, and other company announcements related to its sacropelvic surgical technology platform.
SI-BONE, Inc. expands its product line with the launch of the Granite 9.5 implant, designed for sacroiliac fusion and spinopelvic fixation. The smaller diameter implant received FDA clearance in January 2024. Surgeons praise the implant for its ease of use and potential for improved patient outcomes. The company aims to target a large market with the new offering.
SI-BONE, Inc. reported financial results for the first quarter of 2024, showing worldwide revenue of $37.9 million, a 16% growth from the prior year. The company's U.S. revenue also increased by 16%, with a gross margin of 79%. SI-BONE is optimistic about revenue growth acceleration, driven by new product launches and market expansion. The company updated its 2024 revenue guidance to $164 million - $166 million, indicating a growth of 18% - 20%.
SI-BONE, a medical device company dedicated to musculoskeletal disorders, will be presenting at the 2024 BofA Securities Healthcare Conference. Investors can join the fireside chat on May 14, 2024, at 2:20 p.m. Eastern Time. The webcast will be accessible for replay for 90 days.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.